
Releases
Quantifying Neuroimmune Biomarkers to Accelerate Drug Development
Tracking low-abundance proteins in blood and cerebrospinal fluid remains a primary hurdle in neuroimmunology research. On August 4, 2026, Quanterix will host a webinar detailing how ultrasensitive digital immunoassay technology allows scientists to measure subtle biological changes to better inform patient stratification and clinical trial outcomes.



























